89% of people would be willing to take part in clinical research if they were diagnosed with a medical condition or disease
A new survey conducted on behalf of the National Institute for Health Research Clinical Research Network (NIHR CRN) shows that 89% of people would be willing to take part in clinical research if they were diagnosed with a medical condition or disease – with just 3% saying they would not consider it at all.
The survey also revealed that 95% of people said it was important to them that the National Health Service (NHS) carries out clinical research. NIHR Clinical Research Network's chief executive, Jonathan Sheffield, said: “It is important that we make information about clinical research opportunities widely available to NHS patients, through as many routes as we can. This survey shows that people want to participate and we need to ensure they are made aware of the research opportunities available to them. Through our local Clinical Research Networks, we will continue to actively work withal parts of the NHS to promote research opportunities for patients."
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.